Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

APRIL 21, 2023

In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression. Astellas will license a suite of single-domain antibody (VHH) libraries from Twist for five years to conduct research and development activities.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti.

Development 130

Development Drugs Licensing Licensing 130

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. This is particularly important in developing countries, where access to cold-chain is limited,” said Channon. There are other theoretical advantages as well.

Licensing 119

Licensing Licensing Vaccination Vaccine 119

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Pharmaceutical Technology

OCTOBER 21, 2022

DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing.

Antibody 217

Antibody Protein Licensing Licensing 217

pharmaphorum

NOVEMBER 2, 2021

In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform. If it exercises its option, Novartis will assume responsibility for future development, manufacturing and global commercialisation of therapeutics arising from the alliance.

Protein 98

Protein Licensing Licensing Drugs 98

pharmaphorum

NOVEMBER 15, 2022

The latest deal with Roche covers “multiple targets from a diverse range of target classes,” with Jnana conducting discovery and preclinical activities and Roche responsible for development and commercialisation of any promising candidates. The post Roche deepens ties with Jnana with a second licensing deal appeared first on.

Licensing 105

Licensing Licensing Protein Genetics 105

Pharmaceutical Technology

JUNE 21, 2023

Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX. This protein helps to form blood clots and stop bleeding, with haemophilia B arising when the body is partially or completely unable to produce it.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

pharmaphorum

AUGUST 25, 2021

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 Lilly has bought into Lycia’s lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological disease and pain.

Protein 69

Protein Licensing Licensing Drugs 69

BioTech 365

JULY 13, 2021

Worldwide Targeted Protein Degradation Industry to 2030 – Several Technology Developers Involved in High-value Licensing Deals – ResearchAndMarkets.com Worldwide Targeted Protein Degradation Industry to 2030 – Several Technology Developers Involved in High-value Licensing Deals – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

Licensing 40

Licensing Licensing Protein Development 40

Pharmaceutical Technology

JANUARY 23, 2023

Another key player in the LN market is Aurinia Pharmaceuticals’s Lupkynis, having gained market approval in the US in 2021 and in the EU (licensed to Otsuka Pharmaceutical Co ) in 2022.

Marketing 278

Marketing Production Drugs Trials 278

pharmaphorum

SEPTEMBER 2, 2020

Jounce will lead development of JTX-1811 through IND clearance, after which Gilead will have the sole right to develop the drug. The post Gilead licenses Jounce immunotherapy for $800m appeared first on. The company is perhaps better known for its lead candidate vopratelimab (previously known as JTX-2011).

Licensing 71

Licensing Licensing Antibody Immune Response 71

Pharma Times

OCTOBER 14, 2020

Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development

Licensing 74

Licensing Licensing Protein Development 74

Pharmaceutical Technology

APRIL 4, 2023

Adcendo is developing antibody-drug conjugates (ADCs) to treat cancers with few approved therapies. The company is developing a pipeline of ADCs targeting uPARAP (Endo180), an endocytic collagen receptor that is upregulated in several cancers. When proteins bind to uPARAP, the receptor internalizes and degrades them.

Development 130

Development Licensing Licensing Antibody 130

BioSpace

NOVEMBER 7, 2022

Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech to develop therapeutic antibodies or small molecules that target membrane proteins.

Protein 58

Protein Licensing Licensing Antibody 58

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. The post CanSinoBIO developed a highly effective COVID vaccine with an inhalant version appeared first on.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

The Pharma Data

MARCH 30, 2021

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio.

Protein 52

Protein Licensing Licensing Containment 52

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. It has been developed using the company’s recombinant nanoparticle technology. This is an important step in ensuring broad access to diversified vaccine options.”

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pharmaceutical Technology

SEPTEMBER 22, 2022

AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein. Cystinosis patients have a high deficiency of this protein.

Gene Therapy 147

Gene Therapy Gene Protein Clinical Trials 147

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed based on DARPin technology.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed based on DARPin technology.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

NOVEMBER 1, 2022

An oral inhibitor of exportin 1 (XPO1), Nexpovio works by selectively attaching to hindering the nuclear export protein XPO1. It prevents the tumour suppressor, growth regulatory and anti-inflammatory proteins’ nuclear export, causing their build-up in the nucleus and boosting their anti-cancer activity in the cell.

Protein 130

Protein FDA Approval Production Licensing 130

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Arvinas, Inc.

Protein 52

Protein Development HR Hormones 52

pharmaphorum

MAY 12, 2022

Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down. billion partnership last week. .

Protein 52

Protein Genome Genomics Drugs 52

pharmaphorum

JANUARY 11, 2023

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and immunology. before disease-related proteins are expressed). before disease-related proteins are expressed).

Protein 105

Protein Regulation FDA Approval Licensing 105

BioTech 365

OCTOBER 14, 2020

License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools Technology will be integrated into Rentschler Biopharma’s in-house process with a fast, cost-effective, and stable platform to complement existing CLD offering LAUPHEIM, Germany & … Continue reading (..)

Licensing 40

Licensing Licensing Development Protein 40

pharmaphorum

JANUARY 7, 2022

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months. Tafamidis is thought to work by stabilising the misfolded proteins. The new agreement comes just days after AZ closed a $3.1

Antibody 116

Antibody Licensing Licensing Protein 116

pharmaphorum

DECEMBER 7, 2021

Eplontersen – previously known as IONIS-TTR-L RX – is designed to switch off the production of transthyretin (TTR), a protein which builds up in the disease to toxic levels causing heart problems (cardiomyopathy) and nerve damage (polyneuropathy). In its favour is the potential for less frequent dosing, at least in ATTR polyneuropathy. .

Licensing 59

Licensing Licensing Drugs Marketing 59

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. On obtaining the FDA EUA, the Omicron BA.4/BA.5-adapted 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

Pharmaceutical Technology

FEBRUARY 21, 2023

The US Food and Drug Administration (FDA) has accepted a priority review of the biologics license application (BLA) for Regeneron Pharmaceuticals ’ pozelimab to treat children and adults with ultra-rare CHAPLE disease. C5 is a protein that is involved in the activation of the complement system.

Antibody 130

Antibody FDA Approval Licensing Licensing 130